GET DAILY SIGNALSTG Therapeutics (TGTX) Q3 2026 Earnings Preview: Briumvi Sales in the Spotlight
Key Takeaways
- TG Therapeutics is expected to report its third-quarter 2026 results (quarter ended September 30, 2026) in early November 2026.
- Wall Street consensus points to earnings of roughly $0.37 per share on revenue of approximately $245–247 million, reflecting a sharp year-over-year decline in EPS against a tough prior-year comparison.
- Revenue is forecast to climb roughly 53% year over year, but EPS faces a distorted comparison because Q3 2025 included a one-time income tax benefit of about $365 million.
- U.S. net sales of Briumvi (ublituximab-xiiy), the company's relapsing multiple sclerosis, or RMS, treatment, remain the single most important metric investors will watch.
- The company recently raised its full-year 2026 U.S. Briumvi net revenue guidance to a range of $890–905 million, signaling confidence in continued demand.
- For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the related pages.
- To discover AI-driven trading ideas across the market, explore Trending AI Robots.
Earnings Context and Why It Matters
TG Therapeutics has transformed into a consistently profitable, commercial-stage biopharmaceutical company on the strength of Briumvi, its anti-CD20 therapy for relapsing forms of multiple sclerosis. The third-quarter report matters because it will test whether the drug's double-digit growth can continue in an increasingly competitive market for anti-CD20 MS treatments. In the second quarter, revenue rose about 70% year over year to $240.3 million, yet adjusted EPS disappointed as elevated research and development spending, tied partly to a subcutaneous version of Briumvi, compressed margins. With management raising its 2026 revenue outlook, investors will look for confirmation that demand, pricing, and expense discipline remain on track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect TG Therapeutics to report earnings near $0.37 per share, with consensus revenue estimates clustering between $245 million and $247 million. That revenue figure would represent roughly 53% growth from the $161.7 million reported in the prior-year quarter. The expected EPS decline is misleading, however: last year's third-quarter earnings of $2.43 per share were inflated by a non-recurring deferred tax asset valuation allowance release of about $365 million, rather than underlying operating momentum.
The core number to watch is U.S. Briumvi net sales, which reached about $228 million in Q2 2026. Investors will also monitor operating expense trends, particularly research and development costs tied to the subcutaneous Briumvi program, after elevated spending drove an EPS miss last quarter despite the revenue beat.
Market Reaction and Investor Sentiment
Sentiment heading into the report has been broadly positive. TGTX shares have climbed sharply in 2026, and the stock trades near its 52-week high, reflecting investor enthusiasm for Briumvi's sustained commercial momentum. That strength, however, raises the bar for the print: with the stock already pricing in growth, the market's reaction may hinge less on headline revenue than on the quality of the results and management's commentary. Key risk factors include elevated research and development spending, rising competition in the subcutaneous anti-CD20 space, and any sign that sequential Briumvi growth is decelerating. Investors will be listening closely for updates on full-year guidance and expense expectations.
Forward Outlook and Key Factors to Monitor
Following the third-quarter report, the most important signal will be any change to the company's full-year 2026 outlook. Management has already guided to roughly $950 million in total global revenue, with U.S. Briumvi net sales of $890–905 million. Confirmation, or an upward revision, would reinforce the growth narrative heading into 2027.
Beyond the headline numbers, investors should monitor the subcutaneous Briumvi development timeline. A simplified, subcutaneous dosing option could meaningfully expand the addressable market, but it has also been a source of elevated research and development spending. Progress toward data readouts expected next year will be a key catalyst.
Finally, keep an eye on margin trends and operating expense discipline. While revenue continues to grow rapidly, profitability has been uneven quarter to quarter due to one-time items and investment spending. Sustained operating leverage, alongside stable cash generation, will be essential for the company to build on its recent success without diluting shareholder value.
Using Tickeron’s AI Tools for Deeper Analysis
In preparing for this earnings report, I turned to Tickeron’s AI Screener to quickly filter comparable names in the biotech space and review technical patterns alongside fundamental metrics. The tool helped surface relevant peers and highlight volatility trends that could influence how the market digests the upcoming numbers. It is a practical way to cross-check ideas without spending hours on manual screens, especially when focusing on a single name like TGTX amid broader sector moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TGTX turns positive, indicating new upward trend
TGTX saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 69 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +6.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 254 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 177 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.393) is normal, around the industry mean (3.051). P/E Ratio (19.853) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Due Diligence?
What is Dividend Frequency?
The +127% Surge No One Is Talking About: Trading the Widest Volatility Gap Since the Dot-Com Bubble
AI Trading Robots Beat the Market: Tickeron Bot Delivers strong performance for Retail Investors (GILT)
Q2/Q3 2026 Earnings Preview: August 31–September 3, 2026 | AVGO, DELL, PANW, CRDO, MDB, LULU
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement